Angeliq Regulatory Post Marketing Surveillance.

Trial Profile

Angeliq Regulatory Post Marketing Surveillance.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2013

At a glance

  • Drugs Estradiol/drospirenone (Primary)
  • Indications Menopausal syndrome; Postmenopausal osteoporosis
  • Focus Adverse reactions
  • Acronyms Angeliq rPMS
  • Sponsors Bayer
  • Most Recent Events

    • 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top